Rana McKay – Candidate for ASCO Nominating Committee

Rana McKay has been nominated as the Undesignated Member Candidate of the nomination committee for ASCO.

The ASCO Nominating Committee has selected 13 distinguished members as candidates for leadership positions within the Society.

ASCO encourages all eligible members to vote for the new leaders of the Society.

Eligible members include those holding a Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Medical Science, Doctor of Nursing Science, Doctor of Nursing Practice, or an equivalent doctoral-level degree recognized by the Society and the Association, and who are in good standing as of October 14, 2024. Voting in the ASCO Election will earn eligible members a FASCO point.

The voting period ends on Tuesday, December 3, 2024, at 3:00 PM Eastern Standard Time. All ballots, whether submitted online or by paper, must be received by this deadline.

Rana McKay is nominated alongside Petros Grivas, Erika P. Hamilton, and Flavio G. Rocha.

Rana R. McKay, FASCO, MD, is a board-certified medical oncologist specializing in urogenital cancers, including bladder, kidney, prostate, and testicular cancer.

The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes members for their volunteer engagement, and commitment to ASCO.

Rana McKay has been named as one of the 100 Influential Women in Oncology by OncoDaily. She’s an OncoDaily Editorial Board Member.

Dr. McKay leads a multi-disciplinary prostate cancer clinic at UC San Diego Health, where patients receive coordinated care from a team of specialists, for both early-stage and metastatic prostate cancer.

She is an associate professor in the Department of Medicine at UC San Diego School of Medicine and a Co-Leader of the Genitourinary Oncology Program at the Moores Cancer Center.

Additionally, she is also the Co-Chair for the Hoosier Cancer Research Network Genitourinary Committee and holds several prestigious leadership positions, serving as a member of the NCI Renal Task Force, NCI Prostate Cancer Task Force, National Radiation Oncology Group Renal Cell Carcinoma Cadre Leader, and Alliance Advanced Prostate Cancer Cadre Leader.

She previously served on the National Comprehensive Cancer Network Prostate Cancer Guidelines panel.

Within ASCO, she serves on the Conquer Cancer Grants Selection Committee and is the current track leader of the Annual Meeting Education Program Committee Genitourinary Cancer – Kidney and Bladder track.

She previously served as track leader of the Annual Meeting Scientific Program Committee Genitourinary Cancer – Kidney and Bladder track, and is a member of the ASCO Meeting and Member Publications Editorial Board.

She was formally a member of the Journal of Clinical Oncology Editorial Board

Her research focuses on clinical trials that investigate novel biomarkers and therapies for genitourinary cancers.

Her research is supported through multiple funding mechanisms including the National Institutes of Health, Department of Defense, and foundation grants including the Prostate Cancer Foundation, Kidney Cancer Association, KureIt, Curebound, and others.

Her research interests focus on designing and implementing clinical trials with the use novel biomarkers and therapeutic outcomes for patients with genitourinary malignancies.

She is the principal investigator of several early-phase trials in kidney and prostate cancer, and her work aims to advance personalized cancer treatments and improve patient outcomes.

Dr. McKay has published extensively in leading medical journals, including Nature, The Lancet, and Journal of Clinical Oncology.

Before joining UC San Diego, she was a medical oncologist at Dana-Farber/Brigham and Women’s Cancer Center in Boston and an assistant professor at Harvard Medical School.

Dr. McKay is an active member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), where she contributes to ongoing efforts to improve cancer care.

She is also a graduate of the ASCO Leadership Development Program.

Education

Dr. McKay completed her medical degree and residency at the University of Florida College of Medicine and a fellowship in haematology/oncology at Dana-Farber Cancer Institute/Harvard Medical School. Additionally, she completed a residency in internal medicine at John Hopkins Hospital in Baltimore.

Honors and Awards

Dr. Rana McKay is the recipient of numerous honors and awards which include:

• The 2024 John and Bette Steis Award for kidney cancer research
• The LEAD Award for her leadership in oncology.
• 2015 David Yurman-PCF Young Investigator Award.
• 2023 KCA Trailblazer Award for research on “Dissecting predictors of response to immunotherapy in patients with renal cell carcinoma.”
• 2024 Christopher G. Wood Rising Star Award by IKCS.
• She has been named a Top Doctor in San Diego, recognized by Newsweek as one of America’s Best Prostate Cancer Oncologists.
• The 2024 LEAD Woman Oncologist of the Year.

Interviews with Rana McKay

How to treat Prostate Cancer in 2024 with Dr. Rana McKay – Oncology Brothers (February 2024)

An Interview with Dr. Rana McKay – EMJ (February 2024)

For more posts like this, visit oncodaily.com